𩺠å
§ç§å°ç§èåç
1ïžâ£ DRESS / DIHS + HHV-6
- Drug rash with eosinophilia + systemic symptoms
- Allopurinol, anticonvulsants (carbamazepine, phenytoin), sulfasalazine common precipitants
- HHV-6 reactivation in 50%+ of cases â supports clinical course
- Treatment: stop offending drug + steroid + supportive
- HHV-6 antiviral controversial (not routine)
- Long follow for relapse, autoimmune sequelae
2ïžâ£ ciHHV-6 Clinical Implications
- 1% of population â incidental detection during PCR screening
- Donât treat as active infection
- Tissue or CSF PCR distinguishes (active vs integrated)
- Family screening may identify (autosomal Mendelian inheritance pattern of high viral load)
- Most carriers asymptomatic
3ïžâ£ KS Staging + Treatment Algorithm (AIDS Clinical Trials Group)
- T (tumor): T0 limited cutaneous; T1 visceral / pulmonary
- I (immune): I0 CD4 ⥠150; I1 CD4 < 150
- S (systemic): S0 no symptoms; S1 systemic illness
- Treatment:
- T0I0: ART alone often suffices
- T1 or visceral: ART + chemotherapy
- PEG-liposomal doxorubicin first-line
- Paclitaxel alternative
5ïžâ£ Immune Checkpoint Inhibitor in KS
- Pembrolizumab + nivolumab â some response in advanced KS
- Less effective than HIV virologic suppression with ART
- Used in refractory / progressing despite ART + chemotherapy
6ïžâ£ mTOR Inhibitor for Transplant KS
- Sirolimus or everolimus â anti-KS effect via mTOR pathway inhibition
- Switch from CNI (cyclosporine, tacrolimus) to mTOR-based regimen
- Documented regression of KS in solid organ transplant
- mTOR also has anti-CMV activity
7ïžâ£ å¥ä¿ / Taiwan
- å¥ä¿ valganciclovir, foscarnet, rituximab for indications
- KS â çœèŠ Taiwan; HIV / ç§»æ€ / è幎 ID consult
- HHV-8 PCR â specialty labs
- HHV-6 PCR â research / transplant centers
8ïžâ£ Newer Therapies
- Pomalidomide (immunomodulator) â KS in HIV
- Iberdomide â emerging
- CAR-T for PEL â case reports
- IL-1β inhibitor for KICS â trials